Biomaterial Database

Intra-articular hyaluronic acid (viscosupplementation) for hip osteoarthritis. 2007

S Dagenais

In viscosupplementation, a glycosaminoglycan called hyaluronic acid (HA) is administered via intra-articular injection to patients with osteoarthritis (OA). Two systematic reviews found that HA for hip OA may relieve pain and improve function. Randomized controlled trials had differing results. Uncontrolled studies suggest that there are moderate improvements regarding pain and function for three to six months after HA injection. There is no evidence regarding the cost-effectiveness of this therapy. No serious adverse events have been reported after intra-articular injection of HA for hip OA. The best available evidence suggests that HA may offer symptomatic relief in patients with mild to moderate hip OA for whom other conservative therapies are contraindicated or have failed. Currently, there is insufficient good quality evidence to determine this conclusively.

UI	MeSH Term	Description	Entries
D007270	Injections, Intra-Articular	Methods of delivering drugs into a joint space.	Intra Articular Injection,Intraarticular Injection,Injections, Intraarticular,Intra-Articular Injections,Intraarticular Injections,Articular Injection, Intra,Articular Injections, Intra,Injection, Intra Articular,Injection, Intra-Articular,Injection, Intraarticular,Injections, Intra Articular,Intra Articular Injections,Intra-Articular Injection
D002170	Canada	The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D003362	Cost-Benefit Analysis	A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes.	Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006820	Hyaluronic Acid	A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.	Amo Vitrax,Amvisc,Biolon,Etamucine,Healon,Hyaluronan,Hyaluronate Sodium,Hyvisc,Luronit,Sodium Hyaluronate,Acid, Hyaluronic,Hyaluronate, Sodium,Vitrax, Amo
D015207	Osteoarthritis, Hip	Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.	Coxarthrosis,Osteoarthritis of the Hip,Osteoarthritis Of Hip,Coxarthroses,Hip Osteoarthritis,Osteoarthritis Of Hips
D016032	Randomized Controlled Trials as Topic	Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.	Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018795	Device Approval	Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.	Device Approval Process,New Device Approval,Food and Drug Administration Device Approval,Food and Drug Administration Device Approval Process,New Device Approval Process,Approval Process, Device,Approval Processes, Device,Approval, Device,Approval, New Device,Approvals, Device,Approvals, New Device,Device Approval Processes,Device Approval, New,Device Approvals,Device Approvals, New,New Device Approvals,Process, Device Approval,Processes, Device Approval